Soterix Medical Inc., the global leader in non-invasive stimulation and integrated brain monitoring technologies, announced today clearance from the U.S. Food & Drug Administration (FDA) for the SPRY Transcranial Magnetic Stimulation (TMS) Therapy. SPRY TMS is indicated for the treatment of Major Depressive Disorder in adult patients, who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode.
"For clinicians prioritizing ergonomics and treatment flow, SPRY TMS provides unmatched convenience and performance," said Ms. Gina Polack, VP of Regulatory Affairs of Soterix Medical. "SPRY TMS is a compact multi-protocol all-in-one TMS therapy system." Mr. Kamran Nazim, Chief Product Officer of Soterix Medical adds, "SPRY TMS complements Soterix Medical's unmatched range of non-invasive brain stimulation and measurement systems. And clinicians providing SPRY TMS leverage Soterix Medical's expansive US-based support and training." Psychiatrists in the United States interested in incorporating the SPRY TMS system are eligible for Soterix Medical's Partnership program which includes support on the entire patient set-up pipeline, hands-on training and staff certification, financing options, and connection to our network of psychiatrists. Interested parties should contact Soterix Medical (at contact@soterixmedical.com) for additional information. Disclaimer: Some SPRY TMS accessories are currently investigational (research use) only. See full press release here. Media Contact: Chaya Edelman Tel: +1-888-990-8327 Email: contact@soterixmedical.com
At Soterix Medical Inc., Engineering Serving Humanity means that we're committed to bring the most advanced medical technology into the hands of people who need it. The commitment underpins everything we do.